EUVIMEDEUVIMED entdecken
Systematische ÜbersichtMetaanalyseOpen Access · CC BY-NC 4.0

Weight loss with subcutaneous semaglutide versus other glucagon‐like peptide 1 receptor agonists in type 2 diabetes: a systematic review

Brandon Stretton iD, Joshua Kovoor iD, Stephen Bacchi, Shantel Chang, Benjamin Ngoi, Tess Murray, Thomas C Bristow, Jonathan Heng, Aashray Gupta, Christopher Ovenden, Guy Maddern, Campbell H Thompson iD und 5 weitere

Internal Medicine Journal · 2023

DOI: 10.1111/imj.16126 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift Internal Medicine Journal, 2023. Verfasst von Brandon Stretton und 16 weiteren Autor:innen. Beteiligte Einrichtung: Adelaide Medical School, University of Adelaide, Adelaide, South Australia, Australia. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2. Die Arbeit wurde bisher 26-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Glucagon‐like peptide 1 receptor agonists (GLP‐1 RAs) reduce elevated blood glucose levels and induce weight loss. Multiple GLP‐1 RAs and one combined GLP‐1/glucose‐dependent insulinotropic polypeptide agonist are currently available. This review was conducted with the aim of summarising direct comparisons between subcutaneous semaglutide and other GLP‐1 RAs in individuals with type 2 diabetes (T2D), particularly with respect to efficacy for inducing weight loss and improving other markers of metabolic health. This systematic review of PubMed and Embase from inception to early 2022 was registered on PROSPERO and was conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta‐Analyses and Meta‐Analysis of Observational Studies in Epidemiology guidelines. Of the 740 records identified in the search, five studies fulfilled the inclusion criteria. Comparators included liraglutide, exenatide, dulaglutide and tirzepatide. In the identified studies, multiple dosing regimens were utilised for semaglutide. Randomised trials support the superior efficacy of semaglutide over other GLP‐1 RAs with respect to weight loss in T2D, but tirzepatide is more effective than semaglutide.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 2HumansHypoglycemic AgentsGlucagon-Like Peptide 1Weight LossObservational Studies as TopicSemaglutide

Stichwörter der Autor:innen

obesitytype 2 diabetesweight loss

Substanzen

Hypoglycemic AgentsGlucagon-Like Peptide 1Semaglutide

Autor:innen und Institutionen

  • Adelaide Medical School, University of Adelaide, Adelaide, South Australia, Australia.
  • School of Medicine, Griffith University, Brisbane, Queensland, Australia.
  • Central Adelaide Local Health Network, Adelaide, South Australia, Australia.
  • Gold Coast University Hospital, Brisbane, Queensland, Australia.
  • Metabolic Health Unit, South Australian Health and Medical Research Institute, Adelaide, South Australia, Australia.
  • Northern Adelaide Local Health Network, Adelaide, South Australia, Australia.

ORCID-Profile: Brandon Stretton, Joshua Kovoor, Campbell H Thompson

Zitieren

APA

Stretton, B., Kovoor, J., Bacchi, S., Chang, S., Ngoi, B., Murray, T., Bristow, T. C., Heng, J., Gupta, A., Ovenden, C., Maddern, G., Thompson, C. H., Heilbronn, L., Boyd, M., Rayner, C., Talley, N. J., & Horowtiz, M. (2023). Weight loss with subcutaneous semaglutide versus other glucagon‐like peptide 1 receptor agonists in type 2 diabetes: a systematic review. Internal Medicine Journal. https://doi.org/10.1111/imj.16126

Vancouver

Stretton B, Kovoor J, Bacchi S, Chang S, Ngoi B, Murray T, et al. Weight loss with subcutaneous semaglutide versus other glucagon‐like peptide 1 receptor agonists in type 2 diabetes: a systematic review. Internal Medicine Journal. 2023. doi:10.1111/imj.16126

BibTeX
@article{Stretton2023,
  author = {Stretton, Brandon and Kovoor, Joshua and Bacchi, Stephen and Chang, Shantel and Ngoi, Benjamin and Murray, Tess and Bristow, Thomas C and Heng, Jonathan and Gupta, Aashray and Ovenden, Christopher and Maddern, Guy and Thompson, Campbell H and Heilbronn, Leonie and Boyd, Mark and Rayner, Christopher and Talley, Nicholas J and Horowtiz, Michael},
  title = {Weight loss with subcutaneous semaglutide versus other glucagon‐like peptide 1 receptor agonists in type 2 diabetes: a systematic review},
  journal = {Internal Medicine Journal},
  year = {2023},
  doi = {10.1111/imj.16126}
}
Kostenlos starten →